EP Patent

EP4347554A4 — MC3 LIPIDS AND THEIR USE IN THE PRODUCTION OF LIPIDNAParticles

Assigned to Nanovation Therapeutics Inc · Expires 2025-10-22 · 1y expired

What this patent protects

Patent listed against Onpattro.

Drugs covered by this patent

Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals

Patent Metadata

Patent number: EP4347554A4
Jurisdiction: EP
Classification: —
Expires: 2025-10-22
Drug substance claim: No
Drug product claim: No
Assignee: Nanovation Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.